Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
QP

WKN: A41BEM | ISIN: US74907L4095 | Ticker: 2EB0
Frankfurt
16.11.26 | 08:05
3,000 Euro
-1,32 % -0,040
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
QUOIN PHARMACEUTICALS LTD ADR Chart 1 Jahr
5-Tage-Chart
QUOIN PHARMACEUTICALS LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
3,2203,72017:50
3,2003,56017:23

Aktuelle News zur QUOIN PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoQuoin Pharmaceuticals Ltd. - 8-K, Current Report-
06.11.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals' Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome2
05.11.Quoin Pharmaceuticals GAAP EPS of -$0.971
05.11.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results3
04.11.Quoin Pharmaceuticals Ltd. - 8-K, Current Report-
29.10.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 20262
20.10.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy1
19.10.Canaccord stuft Quoin Pharmaceuticals auf "Buy" hoch - Potenzial bei seltenen Hauterkrankungen im Fokus1
QUOIN PHARMACEUTICALS Aktie jetzt für 0€ handeln
19.10.Canaccord initiates Quoin Pharmaceuticals stock at buy on rare skin disease drug potential2
14.10.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome1
14.10.Quoin Pharmaceuticals Ltd. - 8-K, Current Report1
12.10.BTIG initiates Quoin Pharmaceuticals stock with buy rating3
12.10.BTIG stuft Quoin Pharmaceuticals mit "Buy" ein und sieht erhebliches Kurspotenzial6
06.10.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy271Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton SyndromeCase Report Details Professor Alan Irvine's Clinical Experience Treating a Pediatric Patient Under Quoin's Compassionate...
► Artikel lesen
22.09.Quoin Pharmaceuticals Ltd. - 8-K, Current Report1
22.09.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome299- First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy - Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome - Fast Track Designation Facilitates...
► Artikel lesen
10.09.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU1
31.08.Quoin Pharmaceuticals Raises Up To $50 Million As Financing Could Extend Runway Into Second Half Of 20295
28.08.Quoin Pharmaceuticals, Ltd. - 8-K, Current Report1
28.08.Quoin Pharmaceuticals secures up to $50M financing to fund rare disease pipeline; shares rally5
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1